Tri-Ad5

Tri-Ad5 is an investigational **three-component therapeutic cancer-vaccine regimen** comprising replication-defective recombinant human adenovirus serotype 5 vectors encoding carcinoembryonic antigen-related cell adhesion molecule 5, mucin-1, and brachyury. The three component vaccines are ETBX-011, ETBX-061, and ETBX-051, respectively. Following subcutaneous administration, antigen expression is intended to prime antigen-specific cytotoxic T-cell responses against tumor or premalignant cells expressing these tumor-associated antigens. The vector backbone has deletions in adenoviral E1, E2b, and E3 genes. Tri-Ad5 is being developed by ImmunityBio and is in Phase 2 development with nogapendekin alfa inbakicept for cancer prevention in Lynch syndrome; it is also being studied in combination regimens for metastatic colorectal cancer. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/adenovirus-5-cea-muc1-brachyury-vaccine-tri-ad5))

Brand names

Tri-Ad5Tri-Ad-5Tri-Ad 5

Other names

TriAd5TriAd-5TriAd 5Tri Ad5TriAdenoAd5 CEA/MUC1/brachyury vaccine Tri-Ad5Ad5-CEA/Ad5-MUC1/Ad5-brachyury vaccine Tri-Ad5adenoviral CEA/MUC1/brachyury vaccine Tri-Ad5